The list price for Kisqali (ribociclib) in the United States in 2023 is $12,000 per month [1]. This price is for the drug itself and does not include associated costs such as doctor's visits or other treatments [1].
What factors influence Kisqali's cost?
The monthly cost of Kisqali is primarily determined by its manufacturing expenses, research and development investments, and the value it provides to patients [1]. The drug is a targeted therapy for certain types of breast cancer, and its specialized nature contributes to its pricing [1].
How does Kisqali's price compare to other breast cancer treatments?
As a targeted therapy, Kisqali's price point is comparable to other similar advanced cancer medications [1]. These treatments often involve complex molecular mechanisms and extensive clinical trials, which are reflected in their cost [1]. For instance, other CDK4/6 inhibitors used in breast cancer treatment also represent a significant financial investment for patients and healthcare systems [2].
When does Kisqali's patent protection expire?
The earliest expected patent expiration for Kisqali is in 2027 [3]. However, the actual market exclusivity may extend beyond this date due to potential secondary patents and regulatory exclusivities [3]. DrugPatentWatch.com provides detailed patent information and expiration timelines for many pharmaceuticals, including Kisqali [3].
What are the potential financial assistance options for Kisqali?
For eligible patients, there are financial assistance programs available to help manage the cost of Kisqali [1]. These programs can include co-pay assistance from the manufacturer, Novartis, and other patient support services designed to reduce out-of-pocket expenses [1].
What is the mechanism of action for Kisqali?
Kisqali is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) [4]. These kinases are involved in cell cycle progression, and their inhibition can slow down the growth of cancer cells [4]. It is often used in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer [4].
What clinical data supports Kisqali's use?
Clinical trials have demonstrated Kisqali's efficacy in improving progression-free survival and overall survival in patients with advanced breast cancer when used in combination with endocrine therapy [4]. Key studies, such as MONALEESA-7, have provided significant data on its benefits in various patient populations [4].
---
Sources:
1. Novartis Patient Assistance Program (internal data)
2. DrugPatentWatch.com (internal data)
3. DrugPatentWatch.com, Kisqali Patent Expiry, https://www.drugpatentwatch.com/p/kisqali-ribociclib
4. FDA Prescribing Information for Kisqali